Sign inJoin
Company / Finance

Aclaris Therapeutics, Inc.

ACRS · NASDAQ

Aclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.

FollowAdd to WatchlistAsk Question
NASDAQACRSCoverage BootstrapHealthcareBiotechnologyImmunology
Latest ReportMay 13, 2026Aclaris Therapeutics: the three-shot catalyst stack racing the cash clockView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 company reports
Latest Thesis

Aclaris Therapeutics: the three-shot catalyst stack racing the cash clock

Aclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.

May 13, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Aclaris Therapeutics, Inc.Therapeutics: the three-shot catalyst stack racing the cash clocMay 13, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Aclaris Therapeutics: the three-shot catalyst stack racing the cash clockAclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.NASDAQMay 13, 2026Research reportReadSlides